Santen Pharmaceutical Co. Ltd
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertensio… Read more
Santen Pharmaceutical Co. Ltd (SNPHF) - Total Assets
Latest total assets as of March 2025: $409.28 Billion USD
Based on the latest financial reports, Santen Pharmaceutical Co. Ltd (SNPHF) holds total assets worth $409.28 Billion USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Santen Pharmaceutical Co. Ltd - Total Assets Trend (2005–2025)
This chart illustrates how Santen Pharmaceutical Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Santen Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
Santen Pharmaceutical Co. Ltd's total assets of $409.28 Billion consist of 54.8% current assets and 45.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.7% |
| Accounts Receivable | $71.76 Billion | 17.5% |
| Inventory | $51.59 Billion | 12.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $75.47 Billion | 18.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Santen Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Santen Pharmaceutical Co. Ltd's current assets represent 54.8% of total assets in 2025, a decrease from 59.1% in 2005.
- Cash Position: Cash and equivalents constituted 22.7% of total assets in 2025, up from 17.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 1.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 18.4% of total assets.
Santen Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of Santen Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Santen Pharmaceutical Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Santen Pharmaceutical Co. Ltd generates 0.73x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Santen Pharmaceutical Co. Ltd generates $8.86 in net profit.
Santen Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.58 | 2.54 | 3.35 |
| Quick Ratio | 1.99 | 2.08 | 2.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $137.46 Billion | $ 143.34 Billion | $ 146.72 Billion |
Santen Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Santen Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.03 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -6.1% |
| Total Assets | $409.28 Billion |
| Market Capitalization | $3.47 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Santen Pharmaceutical Co. Ltd's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Santen Pharmaceutical Co. Ltd's assets decreased by 6.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Santen Pharmaceutical Co. Ltd (2005–2025)
The table below shows the annual total assets of Santen Pharmaceutical Co. Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $409.28 Billion | -6.06% |
| 2024-03-31 | $435.70 Billion | +3.45% |
| 2023-03-31 | $421.18 Billion | -8.43% |
| 2022-03-31 | $459.98 Billion | +14.32% |
| 2021-03-31 | $402.35 Billion | -1.57% |
| 2020-03-31 | $408.77 Billion | +4.49% |
| 2019-03-31 | $391.19 Billion | +0.70% |
| 2018-03-31 | $388.46 Billion | +20.35% |
| 2017-03-31 | $322.78 Billion | -9.18% |
| 2016-03-31 | $355.40 Billion | +16.83% |
| 2015-03-31 | $304.20 Billion | +31.63% |
| 2014-03-31 | $231.10 Billion | +15.76% |
| 2013-03-31 | $199.64 Billion | +0.42% |
| 2012-03-31 | $198.80 Billion | +7.58% |
| 2011-03-31 | $184.80 Billion | +10.74% |
| 2010-03-31 | $166.88 Billion | +10.51% |
| 2009-03-31 | $151.01 Billion | -3.54% |
| 2008-03-31 | $156.55 Billion | -1.60% |
| 2007-03-31 | $159.10 Billion | +5.74% |
| 2006-03-31 | $150.46 Billion | +7.49% |
| 2005-03-31 | $139.98 Billion | -- |